Exploring tumor organoids for cancer treatment
Source abstract
Abstract
As a life-threatening chronic disease, cancer is characterized by tumor heterogeneity. This heterogeneity is associated with factors that lead to treatment failure and poor prognosis, including drug resistance, relapse, and metastasis. Therefore, precision medicine urgently needs personalized tumor models that accurately reflect the tumor heterogeneity. Currently, tumor organoid technologies are used to generate in vitro 3D tissues, which have been shown to precisely recapitulate structure, tumor microenvironment, expression profiles, functions, molecular signatures, and genomic alterations in primary tumors. Tumor organoid models are important for identifying potential therapeutic targets, characterizing the effects of anticancer drugs, and exploring novel diagnostic and therapeutic options. In this review, we describe how tumor organoids can be cultured and summarize how researchers can use them as an excellent tool for exploring cancer therapies. In addition, we discuss tumor organoids that have been applied in cancer therapy research and highlight the potential of tumor organoids to guide preclinical research.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Cells and Metastasis · Cancer Genomics and Diagnostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Institute of Translational Medicine, Zhejiang Shuren University 1 , Hangzhou 310015, China
The Third Affiliated Hospital of Wenzhou Medical University 2 , Wenzhou 325200, China
Ningxia Medical University 3 , Ningxia 750004, China
Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University 4 , Changsha 410011, Hunan, China
Funding
Zhejiang Shuren University
References (100+)
Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries10.3322/caac.21660 ↗
2. From structural design to delivery: mRNA therapeutics for cancer immunotherapy10.1002/exp.20210146 ↗
3. Clonal heterogeneity and tumor evolution: Past, present, and the future10.1016/j.cell.2017.01.018 ↗
4. Multi-bioinspired MOF delivery systems from microfluidics for tumor multimodal therapy10.1002/advs.202303818 ↗
5. Sarcoma spheroids and organoids-promising tools in the era of personalized medicine10.3390/ijms19020615 ↗
6. Organoid and spheroid tumor models: Techniques and applications10.3390/cancers13040874 ↗
7. Biomaterials-based approaches to tumor spheroid and organoid modeling10.1002/adhm.201700980 ↗
8. Personalized cancer medicine: An organoid approach10.1016/j.tibtech.2017.12.005 ↗
9. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium10.1053/j.gastro.2011.07.050 ↗
10. A living biobank of breast cancer organoids captures disease heterogeneity10.1016/j.cell.2017.11.010 ↗
11. Basal cells as stem cells of the mouse trachea and human airway epithelium10.1073/pnas.0906850106 ↗
12. Modeling patient-derived glioblastoma with cerebral organoids10.1016/j.celrep.2019.02.063 ↗
13. The role of tumour-stromal interactions in modifying drug response: Challenges and opportunities10.1038/nrd3870 ↗
14. Application of organoids in translational research of human diseases with a particular focus on gastrointestinal cancers10.1016/j.bbcan.2020.188350 ↗
15. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes10.1038/nm.2454 ↗
16. Generation of an inducible colon-specific Cre enzyme mouse line for colon cancer research10.1073/pnas.1614057113 ↗
17. Translational value of mouse models in oncology drug development10.1038/nm.3853 ↗
18. Spherical cancer models in tumor biology10.1016/j.neo.2014.12.004 ↗
19. Measuring mutation accumulation in single human adult stem cells by whole-genome sequencing of organoid cultures10.1038/nprot.2017.111 ↗
20. Cancer modeling meets human organoid technology10.1126/science.aaw6985 ↗
21. Stimuli-responsive gene delivery nanocarriers for cancer therapy10.1007/s40820-023-01018-4 ↗
22. Unraveling mitochondria-targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials10.1002/exp.20220115 ↗
23. Hierarchical microparticles delivering oxaliplatin and NLG919 nanoprodrugs for local chemo-immunotherapy10.1021/acsami.2c16564 ↗
24. Bioengineering-inspired three-dimensional culture systems: Organoids to create tumor microenvironment10.1016/j.gene.2018.11.058 ↗
25. Development of intracytoplasmic lumens in colon cancer cells cultured on non-adhesive surface10.1016/s0940-2993(99)80053-0 ↗
26. A paired bead and magnet array for molding microwells with variable concave geometries10.3791/55548-v ↗
27. Large-scale production of LGR5-positive bipotential human liver stem cells10.1002/hep.31037 ↗
28. Computational fluid dynamic analysis of physical forces playing a role in brain organoid cultures in two different multiplex platforms10.1186/s12861-019-0183-y ↗
29. A reproducible scaffold-free 3D organoid model to study neoplastic progression in breast cancer10.1007/s12079-018-0498-7 ↗
30. Dissecting the stem cell niche with organoid models: An engineering-based approach10.1242/dev.140905 ↗
31. Microfluidic droplet encapsulation-guided organoid growth promotes parental tumor phenotype recapitulation10.1002/ijc.34706 ↗
32. Mammary tumor organoid culture in non-adhesive alginate for luminal mechanics and high-throughput drug screening10.1002/advs.202102418 ↗
33. Organoids by design10.1126/science.aaw7567 ↗
34. Bioprinted multicomponent hydrogel co-culture tumor-immune model for assessing and simulating tumor-infiltrated lymphocyte migration and functional activation10.1021/acsami.3c02995 ↗
35. Growing self-organizing mini-guts from a single intestinal stem cell: Mechanism and applications10.1126/science.1234852 ↗
36. The role of the extracellular matrix in cancer stemness10.3389/fcell.2019.00086 ↗
37. Protease-dependent versus -independent cancer cell invasion programs: Three-dimensional amoeboid movement revisited10.1083/jcb.200807195 ↗
38. Matrigel: Basement membrane matrix with biological activity10.1016/j.semcancer.2005.05.004 ↗
39. Organoid models of human and mouse ductal pancreatic cancer10.1016/j.cell.2014.12.021 ↗
40. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway10.1038/s41417-020-0190-y ↗
41. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy10.3389/fmolb.2019.00160 ↗
42. Modelling cancer in microfluidic human organs-on-chips10.1038/s41568-018-0104-6 ↗
43. Biomaterials and engineered microenvironments to control YAP/TAZ-dependent cell behaviour10.1038/s41563-018-0180-8 ↗
44. Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-410.1186/s12943-019-1091-2 ↗
45. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response10.1186/s13045-021-01103-4 ↗
46. Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids10.1016/j.canlet.2021.06.007 ↗
47. Patient-derived organoids for precision cancer immunotherapy10.1158/0008-5472.can-20-4026 ↗
48. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures10.18632/oncotarget.19965 ↗
49. Organoid modeling of the tumor immune microenvironment10.1016/j.cell.2018.11.021 ↗
50. Murine- and human-derived autologous organoid/immune cell co-cultures as pre-clinical models of pancreatic ductal adenocarcinoma10.3390/cancers12123816 ↗
51. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids10.1016/j.cell.2018.07.009 ↗
52. PDX-derived organoids model in vivo drug response and secrete biomarkers10.1172/jci.insight.135544 ↗
53. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell10.1038/s41388-020-01492-9 ↗
54. Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancer10.1186/s12967-023-04675-6 ↗
55. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening10.1038/nm.4438 ↗
56. RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer10.1158/1078-0432.ccr-22-3335 ↗
57. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity10.1038/s41551-021-00805-x ↗
58. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases10.1186/s12967-021-03062-3 ↗
59. Discovery of a novel CDK7 inhibitor YPN-005 in small cell lung cancer10.1016/j.ejphar.2021.174298 ↗
60. YAP/TAZ suppress drug penetration into hepatocellular carcinoma through stromal activation10.1002/hep.32000 ↗
61. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening10.1038/s41467-019-11867-6 ↗
62. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers10.1126/science.aao2774 ↗
63. Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer10.1158/1078-0432.ccr-20-4116 ↗
64. Human gastric cancer modelling using organoids10.1136/gutjnl-2017-314549 ↗
65. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib10.1093/annonc/mdy542 ↗
66. A rectal cancer organoid platform to study individual responses to chemoradiation10.1038/s41591-019-0584-2 ↗
67. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer10.1016/j.stem.2019.10.010 ↗
68. Tumor evolution and drug response in patient-derived organoid models of bladder cancer10.1016/j.cell.2018.03.017 ↗
69. Model of patient-specific immune-enhanced organoids for immunotherapy screening: Feasibility study10.1245/s10434-019-08143-8 ↗
70. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week10.1038/s41467-021-22676-1 ↗
71. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer10.1158/2159-8290.cd-20-0187 ↗
72. Organoid cultures as preclinical models of non-small cell lung cancer10.1158/1078-0432.ccr-19-1376 ↗
73. Disease modeling on tumor organoids implicates AURKA as a therapeutic target in liver metastatic colorectal cancer10.1016/j.jcmgh.2021.10.008 ↗
74. CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition10.1158/1535-7163.mct-20-0932 ↗
75. Patient-derived tumor chemosensitization of GKB202, an antrodia cinnamomea mycelium-derived bioactive compound10.3390/molecules26196018 ↗
76. Cancer statistics, 202210.3322/caac.21708 ↗
77. Lung cancer epigenetics: From knowledge to applications10.1016/j.semcancer.2017.09.005 ↗
78. Human lung adenocarcinoma-derived organoid models for drug screening10.1016/j.isci.2020.101411 ↗
79. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids10.3390/ijms22031349 ↗
80. Personalized in vitro and in vivo cancer models to guide precision medicine10.1158/2159-8290.cd-16-1154 ↗
81. Long-term expanding human airway organoids for disease modeling10.15252/embj.2018100300 ↗
82. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma10.1158/1078-0432.ccr-20-5026 ↗
83. An in vitro system for evaluating molecular targeted drugs using lung patient-derived tumor organoids10.3390/cells8050481 ↗
84. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles10.1136/gutjnl-2019-320019 ↗
85. Dysregulated pyrimidine biosynthesis contributes to 5-FU resistance in SCLC patient-derived organoids but response to a novel polymeric fluoropyrimidine, CF1010.3390/cancers12040788 ↗
86. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases10.1073/pnas.1516689112 ↗
87. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology10.1016/j.gde.2018.09.001 ↗
88. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis10.1016/j.stem.2016.04.003 ↗
89. Prospective derivation of a living organoid biobank of colorectal cancer patients10.1016/j.cell.2015.03.053 ↗
90. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids10.1038/nm.3802 ↗
91. A genome editing approach to study cancer stem cells in human tumors10.15252/emmm.201707550 ↗
92. Genetic editing of colonic organoids provides a molecularly distinct and orthotopic preclinical model of serrated carcinogenesis10.1136/gutjnl-2017-315920 ↗
93. Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: A phase 2 trial10.1038/s41591-022-02181-8 ↗
94. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: A phase 2, single-center, open-label, and non-comparative study10.1186/s13046-023-02683-4 ↗
95. Circulating microRNA analysis in a prospective Co-clinical trial identifies MIR652-3p as a response biomarker and driver of regorafenib resistance mechanisms in colorectal cancer10.1158/1078-0432.ccr-23-2748 ↗
96. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer10.1038/s41591-023-02240-8 ↗
97. Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy10.1158/1078-0432.ccr-20-0073 ↗
98. Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases10.1186/s13045-020-00957-4 ↗
99. Patient-derived organoids of cholangiocarcinoma10.3390/ijms22168675 ↗
100. Organoid models of human liver cancers derived from tumor needle biopsies10.1016/j.celrep.2018.07.001 ↗